Overview

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Status:
Completed

Trial end date:
2019-09-19

Target enrollment:

Participant gender:

Summary

Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan

Phase:

Phase 2

Details

Lead Sponsor:

Aerie Pharmaceuticals

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions